The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
Fueled by an NIH SBIR grant, analytics firm Cytobank is building out its machine-learning algorithms and adding pipelines to support big-picture research.
Fluidigm reported that its mass cytometry revenues jumped 32 percent while genomics revenues fell 5 percent year over year.
A 30 percent decrease in instrument revenue was tempered by a 23 percent uptick in consumables revenue.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.
The company gains global distribution rights for the Zurich team's histoCAT cytometry imaging software, which it will sell alongside its newly-launched Hyperion Imaging System.
The South San Francisco, California-based single-cell biology firm brought in $25.5 million compared to $29.0 million in the first quarter of 2016.
The researchers used mass cytometry to characterize dozens of markers in 3.5 million immune cells in samples from 73 clear cell renal cell carcinoma patients.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.